New hope for older AML patients: shorter, safer transplant strategy
NCT ID NCT07046078
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This pilot study tests a new treatment plan for adults aged 60 and older with high-risk acute myeloid leukemia (AML) or similar blood cancers. The plan combines a strong chemotherapy regimen (FLAG-Ida) with a lower-intensity stem cell transplant just a few days later. The goal is to kill cancer cells effectively while shortening the time patients have dangerously low blood counts, which can lead to infections and other serious problems. The study will enroll 20 participants to see if this approach is safe and feasible.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
FLAG-Ida chemotherapy (fludarabine, cytarabine, G-CSF, idarubicin) followed by reduced-intensity total body irradiation and donor stem cell transplant
What this could lead to
If this works, it could offer a safer, more effective way to treat older adults with aggressive AML, potentially improving survival and reducing complications from low blood counts.
What could go wrong
This is a small, early-phase pilot study with only 20 participants. The approach is still experimental, and there are risks of infection, bleeding, and other serious side effects. It may not work for everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fred Hutch/University of Washington Cancer Consortium
RECRUITINGSeattle, Washington, 98109, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact